STOCK TITAN

Vanguard (OCGN) disaggregates holdings; reports 0% ownership in Ocugen

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Ocugen Inc common stock ownership filing shows The Vanguard Group reports zero beneficial ownership and 0% of the class. The filing explains an internal realignment of Vanguard effective January 12, 1998 that led certain subsidiaries to report separately. The form is signed by Ashley Grim on 03/27/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated ownership; no reported stake in Ocugen.

The filing lists Amount beneficially owned: 0 and Percent of class: 0%, indicating Vanguard reports no current beneficial position in Ocugen Common Stock in this schedule. The filing references an internal realignment adopted January 12, 1998 as the reason for separate reporting by subsidiaries.

Implications depend on subsidiary filings: subsequent disclosures by Vanguard-affiliated entities could show holdings. Future public filings by those entities would clarify any related positions.

Administrative disclosure reflecting reporting structure, not an economic transaction.

This amendment is a Schedule 13G/A that restates reporting after Vanguard's internal realignment and asserts no beneficial ownership for the filer. The signature block names Ashley Grim as the signatory with date 03/27/2026.

Regulatory readers should treat this as a disclosure of reporting status; any material ownership would appear in separate filings by the specific Vanguard subsidiaries or managed accounts.






67577C105

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does the Ocugen (OCGN) Schedule 13G/A from The Vanguard Group state?

It states The Vanguard Group reports zero beneficial ownership of Ocugen common stock and 0% of the class. The filing attributes separate reporting to an internal realignment referenced on January 12, 1998.

Does this filing mean Vanguard sold Ocugen shares?

No. The filing is an administrative Schedule 13G/A showing Amount beneficially owned: 0 and explains reporting disaggregation after an internal realignment; it does not describe a sale transaction.

Which Vanguard representative signed the filing for OCGN and when?

The filing is signed by Ashley Grim, Head of Global Fund Administration with the signature date shown as 03/27/2026, certifying the amended disclosure on behalf of the filer.

Why does the filing reference SEC Release No. 34-39538 (January 12, 1998)?

The filing cites that release to justify disaggregated reporting: certain Vanguard subsidiaries now report beneficial ownership separately, so The Vanguard Group no longer claims beneficial ownership over those subsidiary-held securities.

Should investors assume no Vanguard-related entity holds OCGN shares?

Not necessarily; this Schedule 13G/A reports zero for The Vanguard Group specifically. Holdings could be reported separately by Vanguard subsidiaries or managed accounts in different filings.
Ocugen Inc

NASDAQ:OCGN

View OCGN Stock Overview

OCGN Rankings

OCGN Latest News

OCGN Latest SEC Filings

OCGN Stock Data

642.68M
319.40M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
MALVERN